The Radiopharmacy Sciences Special Interest Group (SIG) was approved by Council of the Australian and New Zealand Society of Nuclear Medicine to represent Radiochemists and Radiopharmaceutical Scientist members.
The RPS SIG has recently reviewed positively the suggestions provided by an international expert panel, on the best practice for indicating the names of radiopharmaceuticals in scientific and official publications. The guidelines and explanation of the process can be found here.
The current document is a living one, and experts have been invited to provide a feedback. However, it already represents a good term of reference for ANZSNM members to use.
UPDATE ON NOMENCLATURE GUIDELINES, 18 November 2020
On the Consensus Nomenclature Rules for Radiopharmaceutical Chemistry – Reconsideration of Radiochemical Conversion (click HERE to access the article)
Notices (member access only)
2018 RPS SIG AGM Agenda
2018 RPS SIG AGM Notice of Motion
2017 RPS SIG Minutes
Reporting of Abnormal Behaviour of Radiopharmaceuticals
We have had some queries from members about reporting abnormal behaviour with radiopharmaceuticals, however the Society no longer maintains a register for these occurrences. The reporting of these should be undertaken within your organisation's reporting processes including local (state/national) laws as appropriate.
The Society's Radiopharmacy group, led by A/Prof Giancarlo Pascali, is reviewing ways and means whereby feedback and deidentified data can be gathered from the members. This info may allow to determine patterns or issues that are not of a regulatory nature, but could still serve in improving the reliability and safety of radiopharmaceuticals by interfacing with key stakeholders.